|Emory Winship oncology nurse Stephanie McMillan, BSN, OCN, has recently been named to a Bristol-Meyers Squibb nurse advisory panel. As a panel member, McMillan will be participating in reviewing the use and future marketing of the drug dasatinib, which is currently under investigational study funded by the pharmaceutical company. Dasatinib is being studied for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
In clinical trials, dasatinib has demonstrated significant efficacy in the treatment of CML and Ph+ ALL patients who are imatinib-resistant or -intolerant. The promising findings were presented by researchers at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH), which was held in Atlanta this year. In December, Bristol-Meyers Squibb submitted a New Drug Application to the U.S. Food and Drug Administration (FDA), which is the first step in the FDA approval process.
"Winship research physicians have been involved in the clinical studies of using dasatinib since March 2005," said McMillan. "We're encouraged by the responses to the drug that we've seen in our patients enrolled in the trial. This new therapy has the potential to offer a better and more effective treatment for patients experiencing imatinib resistance. As someone who has been involved in the investigational study of this experimental drug, I'm honored to be named as a member of Bristol-Meyers Squibb's advisory panel on it."
McMillan joined the Clinical Trials Office at Emory Winship Cancer Institute in November 2003. She has been an oncology nurse for 24 years, and a certified clinical research professional since 2001. She is also currently president-elect of the metro Atlanta Oncology Nurses Society.